vs

Side-by-side financial comparison of Ardmore Shipping Corp (ASC) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Ardmore Shipping Corp is the larger business by last-quarter revenue ($81.2M vs $75.1M, roughly 1.1× MEDIFAST INC). On growth, Ardmore Shipping Corp posted the faster year-over-year revenue change (-15.5% vs -36.9%). Over the past eight quarters, Ardmore Shipping Corp's revenue compounded faster (-6.0% CAGR vs -34.4%).

Ardmore Shipping Corp is a global maritime transport company that owns and operates a fleet of mid-sized product and chemical tankers. It provides seaborne transport for petroleum products, specialty chemicals and bulk liquid commodities, serving energy, chemical and trading clients across key international trade routes.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

ASC vs MED — Head-to-Head

Bigger by revenue
ASC
ASC
1.1× larger
ASC
$81.2M
$75.1M
MED
Growing faster (revenue YoY)
ASC
ASC
+21.4% gap
ASC
-15.5%
-36.9%
MED
Faster 2-yr revenue CAGR
ASC
ASC
Annualised
ASC
-6.0%
-34.4%
MED

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASC
ASC
MED
MED
Revenue
$81.2M
$75.1M
Net Profit
$12.8M
Gross Margin
69.4%
Operating Margin
16.1%
-10.4%
Net Margin
15.7%
Revenue YoY
-15.5%
-36.9%
Net Profit YoY
-47.0%
EPS (diluted)
$0.30
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASC
ASC
MED
MED
Q4 25
$75.1M
Q3 25
$81.2M
$89.4M
Q2 25
$72.0M
$105.6M
Q1 25
$74.0M
$115.7M
Q4 24
$119.0M
Q3 24
$96.1M
$140.2M
Q2 24
$121.3M
$168.6M
Q1 24
$106.3M
$174.7M
Net Profit
ASC
ASC
MED
MED
Q4 25
Q3 25
$12.8M
$-2.3M
Q2 25
$9.6M
$2.5M
Q1 25
$6.3M
$-772.0K
Q4 24
Q3 24
$24.1M
$1.1M
Q2 24
$62.7M
$-8.2M
Q1 24
$39.2M
$8.3M
Gross Margin
ASC
ASC
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
ASC
ASC
MED
MED
Q4 25
-10.4%
Q3 25
16.1%
-4.6%
Q2 25
13.5%
-1.0%
Q1 25
8.6%
-1.1%
Q4 24
0.6%
Q3 24
25.4%
1.5%
Q2 24
51.3%
-4.7%
Q1 24
37.2%
4.5%
Net Margin
ASC
ASC
MED
MED
Q4 25
Q3 25
15.7%
-2.5%
Q2 25
13.3%
2.3%
Q1 25
8.5%
-0.7%
Q4 24
Q3 24
25.1%
0.8%
Q2 24
51.7%
-4.8%
Q1 24
36.9%
4.8%
EPS (diluted)
ASC
ASC
MED
MED
Q4 25
$-1.64
Q3 25
$0.30
$-0.21
Q2 25
$0.22
$0.22
Q1 25
$0.14
$-0.07
Q4 24
$0.08
Q3 24
$0.55
$0.10
Q2 24
$1.47
$-0.75
Q1 24
$0.92
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASC
ASC
MED
MED
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
$116.1M
Stockholders' EquityBook value
$628.2M
$198.9M
Total Assets
$799.8M
$248.0M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASC
ASC
MED
MED
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Q1 24
$156.4M
Total Debt
ASC
ASC
MED
MED
Q4 25
Q3 25
$116.1M
Q2 25
$25.0M
Q1 25
$20.5M
Q4 24
Q3 24
$22.5M
Q2 24
$44.2M
Q1 24
$23.1M
Stockholders' Equity
ASC
ASC
MED
MED
Q4 25
$198.9M
Q3 25
$628.2M
$214.7M
Q2 25
$618.3M
$216.0M
Q1 25
$610.7M
$211.0M
Q4 24
$210.1M
Q3 24
$627.0M
$207.3M
Q2 24
$617.7M
$205.3M
Q1 24
$567.9M
$211.0M
Total Assets
ASC
ASC
MED
MED
Q4 25
$248.0M
Q3 25
$799.8M
$268.2M
Q2 25
$703.8M
$269.3M
Q1 25
$690.4M
$280.0M
Q4 24
$284.2M
Q3 24
$722.8M
$291.2M
Q2 24
$742.0M
$293.5M
Q1 24
$704.1M
$302.8M
Debt / Equity
ASC
ASC
MED
MED
Q4 25
Q3 25
0.18×
Q2 25
0.04×
Q1 25
0.03×
Q4 24
Q3 24
0.04×
Q2 24
0.07×
Q1 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASC
ASC
MED
MED
Operating Cash FlowLast quarter
$17.9M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
1.40×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASC
ASC
MED
MED
Q4 25
$-5.3M
Q3 25
$17.9M
$12.1M
Q2 25
$11.2M
$-3.4M
Q1 25
$26.3M
$3.4M
Q4 24
$-4.9M
Q3 24
$39.9M
$9.1M
Q2 24
$48.4M
$13.1M
Q1 24
$49.2M
$7.3M
Free Cash Flow
ASC
ASC
MED
MED
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
ASC
ASC
MED
MED
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
ASC
ASC
MED
MED
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
ASC
ASC
MED
MED
Q4 25
Q3 25
1.40×
Q2 25
1.17×
-1.36×
Q1 25
4.20×
Q4 24
Q3 24
1.65×
8.04×
Q2 24
0.77×
Q1 24
1.25×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons